<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35954242</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>15</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Suppression of Linear Ubiquitination Ameliorates Cytoplasmic Aggregation of Truncated TDP-43.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2398</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11152398</ELocationID><Abstract><AbstractText>TAR DNA-binding protein 43 (TDP-43) is a predominant component of inclusions in the brains and spines of patients with amyotrophic lateral sclerosis (ALS). The progressive accumulation of inclusions leads to proteinopathy in neurons. We have previously shown that Met1(M1)-linked linear ubiquitin, which is specifically generated by the linear ubiquitin chain assembly complex (LUBAC), is colocalized with TDP-43 inclusions in neurons from <i>optineurin</i>-associated familial and sporadic ALS patients, and affects NF-&#x3ba;B activation and apoptosis. To examine the effects of LUBAC-mediated linear ubiquitination on TDP-43 proteinopathies, we performed cell biological analyses using full-length and truncated forms of the ALS-associated Ala315&#x2192;Thr (A315T) mutant of TDP-43 in Neuro2a cells. The truncated A315T mutants of TDP-43, which lack a nuclear localization signal, efficiently generated cytoplasmic aggregates that were colocalized with multiple ubiquitin chains such as M1-, Lys(K)48-, and K63-chains. Genetic ablation of <i>HOIP</i> or treatment with a LUBAC inhibitor, HOIPIN-8, suppressed the cytoplasmic aggregation of A315T mutants of TDP-43. Moreover, the enhanced TNF-&#x3b1;-mediated NF-&#x3ba;B activity by truncated TDP-43 mutants was eliminated in the presence of HOIPIN-8. These results suggest that multiple ubiquitinations of TDP-43 including M1-ubiquitin affect protein aggregation and inflammatory responses in vitro, and therefore, LUBAC inhibition ameliorates TDP-43 proteinopathy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pathobiochemistry, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terawaki</LastName><ForeName>Seigo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6019-1628</Identifier><AffiliationInfo><Affiliation>Department of Pathobiochemistry, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular and Genetic Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oikawa</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2897-1779</Identifier><AffiliationInfo><Affiliation>Department of Pathobiochemistry, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okina</LastName><ForeName>Yoshinori</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9306-2176</Identifier><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Usuki</LastName><ForeName>Yoshinosuke</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2308-8693</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Graduate School of Science, Osaka Metropolitan University, Osaka 558-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Hidefumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wakayama Medical University, Wakayama 641-8510, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokunaga</LastName><ForeName>Fuminori</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3626-9119</Identifier><AffiliationInfo><Affiliation>Department of Pathobiochemistry, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000717990">HOIPIN-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006841">Hydrocarbons, Aromatic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006841" MajorTopicYN="N">Hydrocarbons, Aromatic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">LUBAC</Keyword><Keyword MajorTopicYN="N">NF-&#x3ba;B</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">cytoplasmic aggregation</Keyword><Keyword MajorTopicYN="N">ubiquitin</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35954242</ArticleId><ArticleId IdType="pmc">PMC9367985</ArticleId><ArticleId IdType="doi">10.3390/cells11152398</ArticleId><ArticleId IdType="pii">cells11152398</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating S.S., San Gil R., Swanson M.E.V., Scotter E.L., Walker A.K. TDP-43 pathology: From noxious assembly to therapeutic removal. Prog. Neurobiol. 2022;211:102229. doi: 10.1016/j.pneurobio.2022.102229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2022.102229</ArticleId><ArticleId IdType="pubmed">35101542</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A., Bharathi V., Sivalingam V., Girdhar A., Patel B.K. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Xu Y.F., Dickey C.A., Buratti E., Baralle F., Bailey R., Pickering-Brown S., Dickson D., Petrucelli L. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J. Neurosci. 2007;27:10530&#x2013;10534. doi: 10.1523/JNEUROSCI.3421-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3421-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.J., Xu Y.F., Cook C., Gendron T.F., Roettges P., Link C.D., Lin W.L., Tong J., Castanedes-Casey M., Ash P., et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl. Acad. Sci. USA. 2009;106:7607&#x2013;7612. doi: 10.1073/pnas.0900688106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0900688106</ArticleId><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C.C., Bose J.K., Majumder P., Lee K.H., Huang J.T., Huang J.K., Shen C.K. Metabolism and mis-metabolism of the neuropathological signature protein TDP-43. J. Cell Sci. 2014;127:3024&#x2013;3038. doi: 10.1242/jcs.136150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.136150</ArticleId><ArticleId IdType="pubmed">24860144</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning B.A., Walker A.K. The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD. Front. Neurosci. 2019;13:335. doi: 10.3389/fnins.2019.00335.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00335</ArticleId><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenouda M., Xiao S., MacNair L., Lau A., Robertson J. A C-Terminally Truncated TDP-43 Splice Isoform Exhibits Neuronal Specific Cytoplasmic Aggregation and Contributes to TDP-43 Pathology in ALS. Front. Neurosci. 2022;16:868556. doi: 10.3389/fnins.2022.868556.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.868556</ArticleId><ArticleId IdType="pmc">PMC9253772</ArticleId><ArticleId IdType="pubmed">35801182</ArticleId></ArticleIdList></Reference><Reference><Citation>Arseni D., Hasegawa M., Murzin A.G., Kametani F., Arai M., Yoshida M., Ryskeldi-Falcon B. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601:139&#x2013;143. doi: 10.1038/s41586-021-04199-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04199-3</ArticleId><ArticleId IdType="pmc">PMC7612255</ArticleId><ArticleId IdType="pubmed">34880495</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton M.J., Igaz L.M., Wong M.M., Kwong L.K., Trojanowski J.Q., Lee V.M. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 2008;283:13302&#x2013;13309. doi: 10.1074/jbc.M800342200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert Opin. Ther. Targets. 2018;22:279&#x2013;293. doi: 10.1080/14728222.2018.1439923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2018.1439923</ArticleId><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Francois-Moutal L., Perez-Miller S., Scott D.D., Miranda V.G., Mollasalehi N., Khanna M. Structural Insights Into TDP-43 and Effects of Post-translational Modifications. Front. Mol. Neurosci. 2019;12:301. doi: 10.3389/fnmol.2019.00301.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00301</ArticleId><ArticleId IdType="pmc">PMC6934062</ArticleId><ArticleId IdType="pubmed">31920533</ArticleId></ArticleIdList></Reference><Reference><Citation>Komander D., Rape M. The ubiquitin code. Annu. Rev. Biochem. 2012;81:203&#x2013;229. doi: 10.1146/annurev-biochem-060310-170328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-060310-170328</ArticleId><ArticleId IdType="pubmed">22524316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtake F. Branched ubiquitin code: From basic biology to targeted protein degradation. J. Biochem. 2022;171:361&#x2013;366. doi: 10.1093/jb/mvac002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jb/mvac002</ArticleId><ArticleId IdType="pubmed">35037035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirisako T., Kamei K., Murata S., Kato M., Fukumoto H., Kanie M., Sano S., Tokunaga F., Tanaka K., Iwai K. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 2006;25:4877&#x2013;4887. doi: 10.1038/sj.emboj.7601360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601360</ArticleId><ArticleId IdType="pmc">PMC1618115</ArticleId><ArticleId IdType="pubmed">17006537</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikawa D., Sato Y., Ito H., Tokunaga F. Linear Ubiquitin Code: Its Writer, Erasers, Decoders, Inhibitors, and Implications in Disorders. Int. J. Mol. Sci. 2020;21:3381. doi: 10.3390/ijms21093381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093381</ArticleId><ArticleId IdType="pmc">PMC7246992</ArticleId><ArticleId IdType="pubmed">32403254</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahighi S., Ikeda F., Kawasaki M., Akutsu M., Suzuki N., Kato R., Kensche T., Uejima T., Bloor S., Komander D., et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-&#x3ba;B activation. Cell. 2009;136:1098&#x2013;1109. doi: 10.1016/j.cell.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.03.007</ArticleId><ArticleId IdType="pubmed">19303852</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa S., Oikawa D., Ishii R., Ayaki T., Takahashi H., Takeda H., Ishitani R., Kamei K., Takeyoshi I., Kawakami H., et al. Linear ubiquitination is involved in the pathogenesis of optineurin-associated amyotrophic lateral sclerosis. Nat. Commun. 2016;7:12547. doi: 10.1038/ncomms12547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12547</ArticleId><ArticleId IdType="pmc">PMC4999505</ArticleId><ArticleId IdType="pubmed">27552911</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama Y., Tsuji K., Ayaki T., Mori M., Tokunaga F., Ito H. Linear Polyubiquitin Chain Modification of TDP-43-Positive Neuronal Cytoplasmic Inclusions in Amyotrophic Lateral Sclerosis. J. Neuropathol. Exp. Neurol. 2020;79:256&#x2013;265. doi: 10.1093/jnen/nlz135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlz135</ArticleId><ArticleId IdType="pubmed">31951008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama Y., Sakamoto S., Tsuji K., Ayaki T., Tokunaga F., Ito H. Identification of linear polyubiquitin chain immunoreactivity in tau pathology of Alzheimer&#x2019;s disease. Neurosci. Lett. 2019;703:53&#x2013;57. doi: 10.1016/j.neulet.2019.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.03.017</ArticleId><ArticleId IdType="pubmed">30885635</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya K., Hori Y., Oikawa D., Yamamoto T., Umetani K., Urashima T., Kinoshita T., Ayukawa K., Tokunaga F., Tamaru M. High-Throughput Screening for Linear Ubiquitin Chain Assembly Complex (LUBAC) Selective Inhibitors Using Homogenous Time-Resolved Fluorescence (HTRF)-Based Assay System. SLAS Discov. 2018;23:1018&#x2013;1029. doi: 10.1177/2472555218793066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2472555218793066</ArticleId><ArticleId IdType="pubmed">30071751</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuya K., Oikawa D., Iio K., Obika S., Hori Y., Urashima T., Ayukawa K., Tokunaga F. Small-molecule inhibitors of linear ubiquitin chain assembly complex (LUBAC), HOIPINs, suppress NF-&#x3ba;B signaling. Biochem. Biophys. Res. Commun. 2019;509:700&#x2013;706. doi: 10.1016/j.bbrc.2018.12.164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2018.12.164</ArticleId><ArticleId IdType="pubmed">30611571</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikawa D., Sato Y., Ohtake F., Komakura K., Hanada K., Sugawara K., Terawaki S., Mizukami Y., Phuong H.T., Iio K., et al. Molecular bases for HOIPINs-mediated inhibition of LUBAC and innate immune responses. Commun. Biol. 2020;3:163. doi: 10.1038/s42003-020-0882-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-0882-8</ArticleId><ArticleId IdType="pmc">PMC7125101</ArticleId><ArticleId IdType="pubmed">32246052</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuin C., Goodman A., Chernyshev V., Kamentsky L., Cimini B.A., Karhohs K.W., Doan M., Ding L., Rafelski S.M., Thirstrup D., et al. CellProfiler 3.0: Next-generation image processing for biology. PLoS Biol. 2018;16:e2005970. doi: 10.1371/journal.pbio.2005970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.2005970</ArticleId><ArticleId IdType="pmc">PMC6029841</ArticleId><ArticleId IdType="pubmed">29969450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Ma M., Teng J., Che X., Zhang W., Feng S., Zhou S., Zhang Y., Wu E., Ding X. Valproate Attenuates 25-kDa C-Terminal Fragment of TDP-43-Induced Neuronal Toxicity via Suppressing Endoplasmic Reticulum Stress and Activating Autophagy. Int. J. Biol. Sci. 2015;11:752&#x2013;761. doi: 10.7150/ijbs.11880.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.11880</ArticleId><ArticleId IdType="pmc">PMC4466456</ArticleId><ArticleId IdType="pubmed">26078717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling S.C., Polymenidou M., Cleveland D.W. Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Mackenzie I.R., Cairns N.J., Boyer P.J., Markesbery W.R., Smith C.D., Taylor J.P., Kretzschmar H.A., Kimonis V.E., Forman M.S. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J. Neuropathol. Exp. Neurol. 2007;66:152&#x2013;157. doi: 10.1097/nen.0b013e31803020b9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31803020b9</ArticleId><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F., Obi T., Shishido T., Akatsu H., Murayama S., Saito Y., Yoshida M., Hasegawa M. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci. Rep. 2016;6:23281. doi: 10.1038/srep23281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23281</ArticleId><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hans F., Eckert M., von Zweydorf F., Gloeckner C.J., Kahle P.J. Identification and characterization of ubiquitinylation sites in TAR DNA-binding protein of 43 kDa (TDP-43) J. Biol. Chem. 2018;293:16083&#x2013;16099. doi: 10.1074/jbc.RA118.003440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.003440</ArticleId><ArticleId IdType="pmc">PMC6187624</ArticleId><ArticleId IdType="pubmed">30120199</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter E.L., Vance C., Nishimura A.L., Lee Y.B., Chen H.J., Urwin H., Sardone V., Mitchell J.C., Rogelj B., Rubinsztein D.C., et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J. Cell Sci. 2014;127:1263&#x2013;1278. doi: 10.1242/jcs.140087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.140087</ArticleId><ArticleId IdType="pmc">PMC3953816</ArticleId><ArticleId IdType="pubmed">24424030</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin P., Bai D., Zhu L., Deng F., Guo X., Li B., Chen L., Li S., Li X.J. Cytoplasmic TDP-43 impairs the activity of the ubiquitin-proteasome system. Exp. Neurol. 2021;345:113833. doi: 10.1016/j.expneurol.2021.113833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2021.113833</ArticleId><ArticleId IdType="pubmed">34363810</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Well E.M., Bader V., Patra M., Sanchez-Vicente A., Meschede J., Furthmann N., Schnack C., Blusch A., Longworth J., Petrasch-Parwez E., et al. A protein quality control pathway regulated by linear ubiquitination. EMBO J. 2019;38:e100730. doi: 10.15252/embj.2018100730.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018100730</ArticleId><ArticleId IdType="pmc">PMC6484417</ArticleId><ArticleId IdType="pubmed">30886048</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto D., Walinda E., Fukada H., Sou Y.S., Kageyama S., Hoshino M., Fujii T., Tsuchiya H., Saeki Y., Arita K., et al. The unexpected role of polyubiquitin chains in the formation of fibrillar aggregates. Nat. Commun. 2015;6:6116. doi: 10.1038/ncomms7116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7116</ArticleId><ArticleId IdType="pmc">PMC4309437</ArticleId><ArticleId IdType="pubmed">25600778</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado D.A., Davidson B.L. Gene therapy for ALS: A review. Mol. Ther. 2021;29:3345&#x2013;3358. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G., et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho M.A., Baloh R.H., Chakraverty S., Mayo K., Norton J.B., Levitch D., Hatanpaa K.J., White C.L., 3rd, Bigio E.H., Caselli R., et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 2008;63:535&#x2013;538. doi: 10.1002/ana.21344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21344</ArticleId><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Lin L., Tradewell M.L., Dion P.A., Bercier V., Bourgouin P., Rochefort D., Bel Hadj S., Durham H.D., Vande Velde C., et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum. Mol. Genet. 2010;19:671&#x2013;683. doi: 10.1093/hmg/ddp534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp534</ArticleId><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I., Bell S., Cairns N.J., Miller T.M., Baloh R.H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V., Phaneuf D., Bareil C., Robertson J., Rouleau G.A., Kriz J., Julien J.P. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134:2610&#x2013;2626. doi: 10.1093/brain/awr159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr159</ArticleId><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>